Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 13/20 | 1.00 |
| ▸ | GABRD | O14764 | 13/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 13/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 13/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 13/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 13/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 13/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 13/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 13/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 13/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 13/20 | 1.00 |
| ▸ | GABRE | P78334 | 13/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 13/20 | 1.00 |
| ▸ | GABRG1 | Q8N1C3 | 13/20 | 1.00 |
| ▸ | GABRG3 | Q99928 | 13/20 | 1.00 |
| ▸ | GABRQ | Q9UN88 | 13/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30310999 | 1.00 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4627823 | 0.90 | GABRP (0.82) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4607216 | 0.90 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4990126 | 0.86 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16894631 | 0.85 | GABRP (0.81) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5064064 | 0.84 | GABRP (0.80) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6652108 | 0.84 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6656060 | 0.80 | GABRP (0.82) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| 6-Bromoflavone SCHEMBL4449962 | 0.80 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL17179786 | 0.79 | TP53 (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398821-A1 | FLAVONOID DERIVATIVES WITH GABAA RECEPTOR ACTIVITY AND METHODS OF USE | UNIV RUTGERS (US) | 2024-12-05 | — | — | US | disclosed |
| CN-118354770-A | Flavonoid derivatives having GABAA receptor activity and methods of use | 罗特格斯新泽西州立大学 | 2024-07-16 | — | — | CN | disclosed |
| US-8314143-B2 | Synthetic flavonoids and pharmaceutical compositions and therapeutic methods of treatment of HIV infection and other pathologies | FLORIDA A&M UNIVERSITY (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120264820-A1 | Synthetic Flavonoids and Pharmaceutical Compositions and Therapeutic Methods of Treatment of HIV infection and other pathologies | FLORIDA A&M UNIVERSITY | 2012-10-18 | — | — | US | disclosed |
| US-20090312407-A1 | Synthetic Flavonoids and Pharmaceutical Compositions and Therapeutic Methods of Treatment of Cancer and other Pathologies | FLORIDA A&M UNIVERSITY | 2009-12-17 | — | — | US | disclosed |
| EP-1542676-A4 | METHODS OF TREATING BENZODIAZEPINE SITE (BZD-S) ASSOCIATED SYNDROMES USING 2' HYDROXYFLAVONOIDS | PHARMACOGENETICS LTD (CN) | 2008-04-30 | — | — | EP | disclosed |
| EP-1542676-A1 | METHODS OF TREATING BENZODIAZEPINE SITE (BZD-S) ASSOCIATED SYNDROMES USING 2' HYDROXYFLAVONOIDS | Phamacogenetics Limited (CN) | 2005-06-22 | — | — | EP | disclosed |
| US-6740677-B2 | ANXIETY, CONVULSIONS | NATURON LIMITED (HK) | 2004-05-25 | — | — | US | disclosed |
| WO-2004016265-A1 | METHODS OF PREDICTING GABAA RECEPTOR EFFICACIES FOR FLAVONOID COMPOUNDS AND USES THEREFOR | PHAMACOGENETICS LIMITED (CN) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004016266-A1 | METHODS OF TREATING BENZODIAZEPINE SITE (BZD-S) ASSOCIATED SYNDROMES USING 2’ HYDROXYFLAVONOIDS | PHAMACOGENETICS LIMITED (CN) | 2004-02-26 | — | — | WO | disclosed |
| US-20040034092-A1 | Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2' hydroxyflavonoids | NATURON LIMITED (CN) | 2004-02-19 | — | — | US | disclosed |
| EP-0857066-B1 | USE OF NITROFLAVONOIDS FOR THE TREATMENT OF ANXIETY | UNIV STRATHCLYDE (GB) | 2002-05-29 | — | — | EP | disclosed |
| EP-0857066-A1 | USE OF NITROFLAVONOIDS FOR THE TREATMENT OF ANXIETY | University of Strathclyde (GB) | 1998-08-12 | — | — | EP | disclosed |
| WO-1997014414-A1 | USE OF NITROFLAVONOIDS FOR THE TREATMENT OF ANXIETY | UNIVERSITY OF STRATHCLYDE (GB) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264820-A1 | Synthetic Flavonoids and Pharmaceutical Compositions and Therapeutic Methods of Treatment of HIV infection and other pathologies | C5, CD4, C1QBP | GABRP 3425/4885GABRD 4378/4885GABRA1 3714/4885 |
| US-20090312407-A1 | Synthetic Flavonoids and Pharmaceutical Compositions and Therapeutic Methods of Treatment of Cancer and other Pathologies | NRAS, KRAS, TP53 | GABRP 3981/4885GABRD 4522/4885GABRA1 3637/4885 |
| US-20240398821-A1 | FLAVONOID DERIVATIVES WITH GABAA RECEPTOR ACTIVITY AND METHODS OF USE | GABRB1, GABRB2, GABBR1 | GABRP 16/4885GABRD 21/4885GABRA1 6/4885 |
| US-20040034092-A1 | Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2' hydroxyflavonoids | GABBR1, GABBR2, GABRB2 | GABRP 22/4885GABRD 25/4885GABRA1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.